Zenas BioPharma, Ownership
| ZBIO Etf | USD 9.16 0.34 3.58% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Zenas |
Zenas Etf Ownership Analysis
The fund keeps most of the net assets in exotic instruments. Zenas BioPharma, Common last dividend was 0.002 per share. The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States. For more information please call MBA Moulder at 857 271 2954 or visit https://zenasbio.com.Sector Exposure (%)
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on Zenas Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding Zenas BioPharma, , and the less return is expected.
Zenas BioPharma, Common Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zenas BioPharma, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zenas BioPharma,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zenas BioPharma, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Moulder Leon O Jr over a week ago Acquisition by Moulder Leon O Jr of 45000 shares of Zenas BioPharma, at 9.98 subject to Rule 16b-3 | ||
Moulder Leon O Jr over a week ago Acquisition by Moulder Leon O Jr of 25000 shares of Zenas BioPharma, at 10.76 subject to Rule 16b-3 | ||
Moulder Leon O Jr over three weeks ago Acquisition by Moulder Leon O Jr of 2500 shares of Zenas BioPharma, at 14.57 subject to Rule 16b-3 | ||
Moulder Leon O Jr over three weeks ago Acquisition by Moulder Leon O Jr of 7500 shares of Zenas BioPharma, at 15.0 subject to Rule 16b-3 |
Pair Trading with Zenas BioPharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zenas BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will appreciate offsetting losses from the drop in the long position's value.Moving against Zenas Etf
| 0.67 | VAXX | Vaxxinity | PairCorr |
| 0.67 | CEROW | CERo Therapeutics Symbol Change | PairCorr |
| 0.56 | ENZN | Enzon Pharmaceuticals | PairCorr |
| 0.53 | EPRX | Eupraxia Pharmaceuticals | PairCorr |
| 0.53 | EVLO | Evelo Biosciences | PairCorr |
The ability to find closely correlated positions to Zenas BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zenas BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zenas BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zenas BioPharma, Common to buy it.
The correlation of Zenas BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zenas BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zenas BioPharma, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zenas BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.